IL2 and lung carcinoma: MART-1scTCR-IL-2 has not been tested in a MART-1-positive tumor model but showed partial antitumor efficacy in a lung cancer model tumor in which the increased half-life of IL-2 was propose as a supporting factor underlying efficacy [124].